GLP-1s and Fatty Liver

The short answer

GLP-1 medications are not yet FDA-approved for fatty liver disease, but the evidence supporting their use is among the strongest in any liver pharmacology pipeline. The ESSENCE trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) showed significant resolution of steatohepatitis and, at higher doses, improvement in liver fibrosis. Tirzepatide showed similar results in SYNERGY-NASH. A label expansion for MASH is widely expected.

What the research shows

The terminology has shifted. What used to be called non-alcoholic fatty liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD). Its inflammatory, fibrosing form — formerly NASH — is now metabolic dysfunction-associated steatohepatitis (MASH). The renaming reflects the underlying biology: this is a metabolic disease, driven by insulin resistance, visceral adiposity, and metabolic syndrome.

ESSENCE, published in 2025, was the pivotal phase 3 trial of semaglutide in biopsy-confirmed MASH. It enrolled roughly 1,200 adults with stage F2 or F3 fibrosis and randomized them to semaglutide 2.4 mg weekly or placebo for 72 weeks, with paired liver biopsies. Two co-primary endpoints: resolution of steatohepatitis without worsening fibrosis, and improvement in fibrosis without worsening steatohepatitis. Semaglutide hit both. Steatohepatitis resolution occurred in roughly 63% of the semaglutide group vs. 34% of placebo; fibrosis improvement in roughly 37% vs. 22%.

Tirzepatide produced similarly strong results in SYNERGY-NASH (phase 2). Across multiple doses, steatohepatitis resolution rates reached 44–62% on tirzepatide vs. 10% on placebo. Fibrosis improvement showed a clear dose response. The phase 3 program is ongoing, with results expected to mirror ESSENCE in magnitude.

Steatosis without inflammation (simple MASLD) is also responsive, but the bar for biopsy-confirmed change is harder to study. Imaging endpoints — MRI-PDFF for hepatic fat fraction and FibroScan for stiffness — improve significantly on both semaglutide and tirzepatide in this group, with hepatic fat reductions of 30–50%. Liver enzymes (ALT, AST) typically normalize for most patients within 6 months.

How it tends to work in practice

For a patient with elevated liver enzymes and imaging showing steatosis but no significant fibrosis (early MASLD), a GLP-1 is increasingly the first metabolic intervention recommended after lifestyle change. Weight loss in the 5–10% range produces substantial hepatic fat reduction; loss in the 10–15% range is associated with biopsy-level improvement in steatohepatitis; loss beyond 15% drives fibrosis regression in a meaningful fraction of patients. The dose-response between weight loss and liver outcome is one of the cleanest signals in metabolic medicine.

The patients who tend to respond most are those with the classic metabolic phenotype — central obesity, insulin resistance, prediabetes or T2D, and dyslipidemia. Patients with leaner MASH or a strong genetic component (PNPLA3 variants, for instance) may have less dramatic responses because weight loss isn't addressing as much of the driver.

What hepatologists watch in the first 6 months: ALT and AST trajectories (usually drop within 8–12 weeks), FibroScan stiffness change at 6–12 months, body weight trajectory, and any gallbladder symptoms — rapid weight loss is a known precipitant of gallstones, and GLP-1s carry a small additional gallbladder signal independent of weight loss. Most specialists also strongly counsel near-abstinence from alcohol during the treatment period, because alcohol can blunt liver improvement even at low doses.

Common questions

Keep exploring

Browse all GLP-1 guides.